These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Identification and antifungal susceptibility of Candida spp isolated from invasive mycoses. Influence of growth inhibition percentage to determine minimal inhibitory concentration]. Alvarado D, Díaz MC, Silva V. Rev Med Chil; 2002 Apr; 130(4):416-23. PubMed ID: 12090107 [Abstract] [Full Text] [Related]
3. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts. Mondello F, De Bernardis F, Girolamo A, Salvatore G, Cassone A. J Antimicrob Chemother; 2003 May; 51(5):1223-9. PubMed ID: 12668571 [Abstract] [Full Text] [Related]
5. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Swinne D, Watelle M, Van der Flaes M, Nolard N. Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180 [Abstract] [Full Text] [Related]
6. Antifungal activities of azole agents against the Malassezia species. Miranda KC, de Araujo CR, Costa CR, Passos XS, de Fátima Lisboa Fernandes O, do Rosário Rodrigues Silva M. Int J Antimicrob Agents; 2007 Mar; 29(3):281-4. PubMed ID: 17223320 [Abstract] [Full Text] [Related]
12. Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Rex JH, Leitz GJ, Ostrosky-Zeichner L. Mycoses; 2010 Sep; 53(5):438-42. PubMed ID: 19500259 [Abstract] [Full Text] [Related]
13. [Comparative sensitivity of yeasts to ketoconazole, itraconazole and fluconazole using a liquid medium standardized micromethod]. Guinet R, Marlier H. Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):575-8. PubMed ID: 2166937 [Abstract] [Full Text] [Related]
16. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, Eliopoulou C, Destouni E, Antoniades D. Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459 [Abstract] [Full Text] [Related]
18. Azole resistance in Candida albicans. Smith KJ, Warnock DW, Kennedy CT, Johnson EM, Hopwood V, Van Cutsem J, Vanden Bossche H. J Med Vet Mycol; 1986 Apr; 24(2):133-44. PubMed ID: 3014106 [Abstract] [Full Text] [Related]
19. [Investigation of quantitative and species composition and antifungal drug susceptibility of yeasts isolated from patients with generalized periodontitis complicated by candidosis]. Kutsyk RV, Pavliuk TD. Mikrobiol Z; 2003 Apr; 65(5):26-9. PubMed ID: 14723159 [Abstract] [Full Text] [Related]
20. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT. Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726 [Abstract] [Full Text] [Related] Page: [Next] [New Search]